131 related articles for article (PubMed ID: 36208507)
21. Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.
Borges VF; Ferrario C; Aucoin N; Falkson C; Khan Q; Krop I; Welch S; Conlin A; Chaves J; Bedard PL; Chamberlain M; Gray T; Vo A; Hamilton E
JAMA Oncol; 2018 Sep; 4(9):1214-1220. PubMed ID: 29955792
[TBL] [Abstract][Full Text] [Related]
22. Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects.
Topletz-Erickson AR; Lee AJ; Mayor JG; Rustia EL; Abdulrasool LI; Wise AL; Dailey B; DeChenne S; Walker LN; Alley SC; Endres CJ
J Clin Pharmacol; 2021 Apr; 61(4):461-471. PubMed ID: 32989831
[TBL] [Abstract][Full Text] [Related]
23. Neratinib: an option for HER2-positive metastatic breast cancer.
O'Shaughnessy JA; O'Regan R; Isaacs C
Clin Adv Hematol Oncol; 2020 Sep; 18 Suppl 15(9):1-20. PubMed ID: 33843838
[TBL] [Abstract][Full Text] [Related]
24. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
25. HER2-positive metastatic breast cancer: a comprehensive review.
Exman P; Tolaney SM
Clin Adv Hematol Oncol; 2021 Jan; 19(1):40-50. PubMed ID: 33493147
[TBL] [Abstract][Full Text] [Related]
26. Discovery of novel VEGFR-2-PROTAC degraders based on the localization of lysine residues via recruiting VHL for the treatment of gastric cancer.
Wang XR; Wang S; Mu HX; Xu KY; Wang XT; Shi JT; Cui QH; Zhang LW; Chen SW
Eur J Med Chem; 2022 Dec; 244():114821. PubMed ID: 36242985
[TBL] [Abstract][Full Text] [Related]
27. Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors.
Floros KV; Jacob S; Kurupi R; Fairchild CK; Hu B; Puchalapalli M; E Koblinski J; Dozmorov MG; Boikos SA; Scaltriti M; Faber AC
Cell Death Dis; 2021 Feb; 12(2):179. PubMed ID: 33589591
[TBL] [Abstract][Full Text] [Related]
28. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
29. Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer.
Corti C; Criscitiello C
ESMO Open; 2021 Apr; 6(2):100063. PubMed ID: 33676293
[No Abstract] [Full Text] [Related]
30. Current treatment options for HER2-positive breast cancer patients with brain metastases.
Galanti D; Inno A; La Vecchia M; Borsellino N; Incorvaia L; Russo A; Gori S
Crit Rev Oncol Hematol; 2021 May; 161():103329. PubMed ID: 33862249
[TBL] [Abstract][Full Text] [Related]
31. UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells.
Hua J; Zhang Z; Zhang L; Sun Y; Yuan Y
Cancer Chemother Pharmacol; 2021 Oct; 88(4):633-642. PubMed ID: 34146128
[TBL] [Abstract][Full Text] [Related]
32. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
Murthy R; Borges VF; Conlin A; Chaves J; Chamberlain M; Gray T; Vo A; Hamilton E
Lancet Oncol; 2018 Jul; 19(7):880-888. PubMed ID: 29804905
[TBL] [Abstract][Full Text] [Related]
33. [Not Available].
Bachelot T; Bailleux C; Darlix A; Jacot W
Bull Cancer; 2021 Dec; 108(11S):11S26-11S34. PubMed ID: 34969513
[TBL] [Abstract][Full Text] [Related]
34. HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis, and
Elwaie TA; Abbas SE; Aly EI; George RF; Ali H; Kraiouchkine N; Abdelwahed KS; Fandy TE; El Sayed KA; Abd Elmageed ZY; Ali HI
J Med Chem; 2020 Dec; 63(24):15906-15945. PubMed ID: 33314925
[TBL] [Abstract][Full Text] [Related]
35. Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box.
Tarantino P; Prat A; Cortes J; Cardoso F; Curigliano G
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188487. PubMed ID: 33259892
[TBL] [Abstract][Full Text] [Related]
36. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
Lee J; Bartholomeusz C; Mansour O; Humphries J; Hortobagyi GN; Ordentlich P; Ueno NT
Breast Cancer Res Treat; 2014 Jul; 146(2):259-72. PubMed ID: 24916181
[TBL] [Abstract][Full Text] [Related]
37. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
[TBL] [Abstract][Full Text] [Related]
38. Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
Nonagase Y; Yonesaka K; Kawakami H; Watanabe S; Haratani K; Takahama T; Takegawa N; Ueda H; Tanizaki J; Hayashi H; Yoshida T; Takeda M; Chiba Y; Tamura T; Nakagawa K; Tsurutani J
Oncotarget; 2016 Dec; 7(51):84860-84871. PubMed ID: 27768588
[TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
40. Current and Future Management of HER2-Positive Metastatic Breast Cancer.
Martínez-Sáez O; Prat A
JCO Oncol Pract; 2021 Oct; 17(10):594-604. PubMed ID: 34077236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
